GRCE
Grace Therapeutics, Inc.
$2.37
+0.13 (+5.80%)
At close · Jul 2
Market Cap
$38.57M
Shares
16,274,026
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.37
Open$2.26
Day$2.26–2.39
52W$1.79–5.11
Avg vol 30d271K
Short int1.9M · 11.7% float · 7.0d
Short vol37%
Last earningsJun 18, 2026
DataJan 2020–Jul 2026
Filing10-K · Jun 18
Equibles Rating
blended score · not investment advice
Overall
Strong Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−27% below
+
Price vs 50-day avg
+1% above
◦
RSI (14)
50 · neutral
+
MACD trend
positive
◦
52-week position
17% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $3 — 200d above 50d
+
Institutional flow
+59% holders QoQ · +19 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
11.69% of float · ▼ -5.6% MoM · 7.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
35 holders — near 1-yr high, broad support
Fundamentals
Excellent
+
EPS growth
+41% Y/Y
+
Balance sheet
net cash $17.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Sep 18, 2026
Est · unconfirmed
· in 11 wks
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Jun 18, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−27% below
Bearish
Price vs 50-day avg
+1% above
Bullish
RSI (14)
50 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
17% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+59% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.69% of float · ▼ -5.6% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 17%
52-wk high $5
vs 200-day avg -27%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRCE
this stock
Grace Therapeutics, Inc.
|
$38.57M | -31.5% | — | — | 11.7% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRCE | +0.0% | -3.3% | -37.6% | +4.4% | -31.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -1.4% | -2.0% | -45.7% | +4.7% | -40.7% |
Key facts
CIK
1444192
CUSIP
00439U104